Dr. Schiffman is the CEO and Co-Founder of PEEL Therapeutics, delivering evolution-inspired medicine to patients. He also co-founded ItRunsInMyFamily.com, an online family history collection tool. Dr. Schiffman is a Professor of Pediatrics and Investigator at Huntsman Cancer Institute at the University of Utah and the Medical Director for the Family Cancer Assessment Clinic. He also works as a Pediatric Hematologist-Oncologist at Intermountain Primary Children’s Hospital in Salt Lake City, Utah. Dr. Schiffman graduated from the Brown University School of Medicine in 2000, followed by clinical training in Pediatrics and Pediatric Hematology-Oncology at Stanford University from 2000-2008. His academic research and now commercial efforts focus on genomic development of cancer in children and studying animals that naturally are protected from cancer, like elephants. Dr. Schiffman has co-founded several exciting new startup companies to impact cancer diagnosis, treatment, and prevention.
Emerging Therapeutics Showcase:
PEEL Therapeutics, Inc. is an emerging biotech that delivers evolution-inspired medicines to improve patient lives. The PEEL pipeline originates from assets inspired by the evolution of elephants, plants, and humans for the treatment of cancer and a wide range of inflammatory diseases.
Delivering Evolution Inspired Medicines For Patients
Modern lifestyle results in diseases like cancer, CVD, and diabetes. Through evolution, nature has avoided many of these same diseases in plants and animals (elephants prevent cancer, bears hibernate without diabetes or heart disease, dolphins dive thousands of feet without blood clots). PEEL Therapeutics is using cutting-edge nanotechnology to develop new medicines and translate evolution's molecules into bioavailable, life-saving drugs. This presentation will cover PEEL's pipeline including new drugs based on the evolution of elephants, plants, and humans for the treatment of cancer and a wide range of inflammatory diseases.
The PMWC 2020 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.